MX2020007375A - Terapias de combinacion para el tratamiento de carcinoma hepatocelular. - Google Patents
Terapias de combinacion para el tratamiento de carcinoma hepatocelular.Info
- Publication number
- MX2020007375A MX2020007375A MX2020007375A MX2020007375A MX2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A MX 2020007375 A MX2020007375 A MX 2020007375A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- hepatocellular carcinoma
- combination therapies
- combination
- lenvatinib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615848P | 2018-01-10 | 2018-01-10 | |
| PCT/US2019/012886 WO2019139977A1 (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007375A true MX2020007375A (es) | 2020-11-09 |
Family
ID=65411938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007375A MX2020007375A (es) | 2018-01-10 | 2019-01-09 | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11833119B2 (https=) |
| EP (2) | EP4667005A3 (https=) |
| JP (2) | JP7352569B2 (https=) |
| KR (2) | KR102811519B1 (https=) |
| CN (1) | CN111787922A (https=) |
| AU (1) | AU2019206480A1 (https=) |
| BR (1) | BR112020014112A2 (https=) |
| CA (1) | CA3088292A1 (https=) |
| IL (1) | IL275981A (https=) |
| MA (1) | MA51570A (https=) |
| MX (1) | MX2020007375A (https=) |
| SG (1) | SG11202006617RA (https=) |
| WO (1) | WO2019139977A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| JP2025520303A (ja) * | 2022-05-30 | 2025-07-03 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 癌治療用の医薬組み合わせ物および医薬組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| KR100804566B1 (ko) | 2003-12-25 | 2008-02-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법 |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| EP2809312A1 (en) | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
| BR112015029386B1 (pt) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| PH12016500676B1 (en) * | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| HRP20210319T1 (hr) * | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije inhibitora fgfr i inhibitora igf1r |
| US20160089365A1 (en) | 2014-09-25 | 2016-03-31 | Eisai R&D Management Co., Ltd. | Immunostimulatory compound |
| KR102548229B1 (ko) | 2015-04-14 | 2023-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 결정질 fgfr4 억제제 화합물 및 그의 용도 |
| CN107304188A (zh) | 2016-04-20 | 2017-10-31 | 成都融科博海科技有限公司 | 一种氘代激酶选择性抑制剂及其应用 |
| JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
-
2019
- 2019-01-09 MA MA051570A patent/MA51570A/fr unknown
- 2019-01-09 WO PCT/US2019/012886 patent/WO2019139977A1/en not_active Ceased
- 2019-01-09 EP EP25207224.4A patent/EP4667005A3/en active Pending
- 2019-01-09 US US16/961,292 patent/US11833119B2/en active Active
- 2019-01-09 AU AU2019206480A patent/AU2019206480A1/en not_active Abandoned
- 2019-01-09 JP JP2020558858A patent/JP7352569B2/ja active Active
- 2019-01-09 EP EP19705261.6A patent/EP3737377B1/en active Active
- 2019-01-09 MX MX2020007375A patent/MX2020007375A/es unknown
- 2019-01-09 KR KR1020207022999A patent/KR102811519B1/ko active Active
- 2019-01-09 KR KR1020257016389A patent/KR20250073570A/ko active Pending
- 2019-01-09 CA CA3088292A patent/CA3088292A1/en active Pending
- 2019-01-09 CN CN201980015321.XA patent/CN111787922A/zh active Pending
- 2019-01-09 BR BR112020014112-7A patent/BR112020014112A2/pt not_active IP Right Cessation
- 2019-01-09 SG SG11202006617RA patent/SG11202006617RA/en unknown
-
2020
- 2020-07-12 IL IL275981A patent/IL275981A/en unknown
-
2023
- 2023-09-15 JP JP2023149903A patent/JP7665700B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL275981A (en) | 2020-08-31 |
| JP7665700B2 (ja) | 2025-04-21 |
| US11833119B2 (en) | 2023-12-05 |
| EP4667005A2 (en) | 2025-12-24 |
| JP2021512140A (ja) | 2021-05-13 |
| MA51570A (fr) | 2020-11-18 |
| RU2020126673A3 (https=) | 2022-04-19 |
| CN111787922A (zh) | 2020-10-16 |
| EP3737377A1 (en) | 2020-11-18 |
| EP4667005A3 (en) | 2026-02-18 |
| WO2019139977A1 (en) | 2019-07-18 |
| US20200360371A1 (en) | 2020-11-19 |
| AU2019206480A1 (en) | 2020-08-27 |
| KR20200121302A (ko) | 2020-10-23 |
| KR102811519B1 (ko) | 2025-05-22 |
| BR112020014112A2 (pt) | 2020-12-01 |
| EP3737377B1 (en) | 2025-10-08 |
| JP7352569B2 (ja) | 2023-09-28 |
| KR20250073570A (ko) | 2025-05-27 |
| JP2023175825A (ja) | 2023-12-12 |
| RU2020126673A (ru) | 2022-02-10 |
| CA3088292A1 (en) | 2019-07-18 |
| SG11202006617RA (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| IL282727A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| JOP20190272A1 (ar) | مثبطات kras g12c وطرق لاستخدامها | |
| CY1122283T1 (el) | Συνδυασμος ενος αντισωματος cd30xcd16a με ενα ανταγωνιστικο αντισωμα αντι-pd-1 για θεραπεια | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
| MX2017008844A (es) | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
| EA201692436A1 (ru) | Медицинское применение | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| MX2020013728A (es) | Combinacion de inmunoterapias con inhibidores de mdm2. | |
| MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
| MX2019009908A (es) | Combinacion de un agonista de ppar con un agonista de fxr. | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| BR112019003722A2 (pt) | terapias de combinação para o tratamento de carcinoma hepatocelular | |
| MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
| MX2020007375A (es) | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. | |
| WO2019170283A8 (en) | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). |